We work closely with healthcare professionals to develop robotic solutions for treating vascular diseases such as heart attack and stroke. Our first solution, R-One+™, is designed to assist with PCI, the gold standard for coronary artery diseases.
Professor E. Durand, interventional cardiologist at Rouen University Hospital (France)
There are very clear advantages for the physician in terms of precision, which indirectly benefit the patient.
Doctor J. Fajadet, co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse (France), co-director of EuroPCR congress and Director of the EAPCI
The precision in the manipulation of the wire and the balloon/stent catheter is really exceptional.
Professor M. Haude, interventional cardiologist and Director of Medical Clinic I at Rheinland Klinikum Neuss, Lukaskrankenhaus (Germany)
The benefits brought by R-One™ are huge for practitioners and will drastically improve our working conditions, which will consequently benefit patient care.
Professor F. Lorgat, interventional cardiologist, Netcare Christiaan Barnard Memorial Hospital (South-Africa)
I have been following this project closely for several years, as my experience with robotics in electrophysiology has clearly shown me all the benefits that such devices can have for our profession and ultimately, for the patient.
Professor S. Verheye, interventional cardiologist at ZNA Middelheim in Antwerp (Belgium)
I was immediately impressed by the platform’s ease of use and its level of precision. The robot places the stent even more precisely than with the manual technique, down to a fraction of a millimeter.
Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes smart robotic solutions to treat cardiovascular diseases. As an active player in the digital evolution of the medical industry, its smart connected solutions aim to enhance hand gestures and make medical procedures safer. Robocath develops robotic solutions which integrate a unique bionic technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. Robocath’s robotic solutions are designed to operate with precision and perform accurate movements, creating better interventional conditions. Thanks to their open architecture, they are all compatible with market-leading devices and cathlabs. The company received the CE marking for R-One, its first robotic solution, in 2019. In a prospective, multicenter, non-randomized, single-arm clinical trial, R-One demonstrated safety and efficacy as it achieved more than 95% technical procedure success with no MACE (major adverse cardiovascular events). Currently R-One is used in Europe, Africa and China. By pursuing the development of smart digital solutions, Robocath aims to become a world leader in vascular robotics. Based in Rouen, France, Robocath has more than 70 employees.